for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cara Therapeutics Inc

CARA.OQ

Latest Trade

16.57USD

Change

0.17(+1.04%)

Volume

306,390

Today's Range

16.49

 - 

17.60

52 Week Range

12.20

 - 

27.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
16.40
Open
16.49
Volume
306,390
3M AVG Volume
15.43
Today's High
17.60
Today's Low
16.49
52 Week High
27.50
52 Week Low
12.20
Shares Out (MIL)
46.68
Market Cap (MIL)
773.47
Forward P/E
-6.48
Dividend (Yield %)
--

Latest Developments

More

Cara Therapeutics Reports Data From Phase 2 Trial Of Korsuva

Cara Therapeutics Announces Publication Of Difelikefalin KALM-1 Phase 3 Trial Results

Cara Therapeutics Inc Reports Q3 Loss Per Share Of $0.74

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cara Therapeutics Inc

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.

Industry

Biotechnology & Drugs

Contact Info

4 Stamford Plz

+1.203.4063700

http://www.caratherapeutics.com/

Executive Leadership

Derek T. Chalmers

President, Chief Executive Officer, Director

Mani Mohindru

Chief Financial Officer, Chief Strategy Officer

Frederique Menzaghi

Chief Scientific Officer

Scott M. Terrillion

Chief Compliance Officer, General Counsel, Secretary

Joana Goncalves

Chief Medical Officer

Key Stats

1.67 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.100

2017

-1.860

2018

-2.060

2019(E)

-2.556
Price To Earnings (TTM)
--
Price To Sales (TTM)
36.99
Price To Book (MRQ)
3.65
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-51.13
Return on Equity (TTM)
-41.31

Latest News

Latest News

Cara Therapeutics signs licensing deal with Vifor Fresenius, shares surge

Shares of Cara Therapeutics surged more than 20 percent on Wednesday after it signed a licensing agreement with Vifor Fresenius Medical Care Renal Pharma Ltd that could give the U.S. drug developer up to $470 million in milestone payments.

BRIEF-Cara Therapeutics And Vifor Fresenius Medical Care Renal Pharma Enter Into Ex-U.S. Licensing Agreement

* CARA THERAPEUTICS AND VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA (VFMCRP) ENTER INTO EX-U.S. LICENSING AGREEMENT TO COMMERCIALIZE KORSUVA™ INJECTION IN DIALYSIS PATIENTS WITH PRURITUS

BRIEF-Vifor Pharma: VFMCRP And Cara Therapeutics To Develop And Commercialise CR845 Injection For Chronic Kidney Disease-Associated Pruritus

* VFMCRP AND CARA THERAPEUTICS TO DEVELOP AND COMMERCIALISE CR845 INJECTION FOR CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cara Therapeutics Reports Q1 Loss Per Share $0.51

* CARA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Cara Therapeutics Reports Q4 Loss Per Share $0.43

* CARA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Cara Therapeutics Inc reports Q3 loss per share $0.38

* Cara Therapeutics Inc reports third quarter 2017 financial results

BRIEF-Cara Therapeutics Q2 loss per share $0.29

* Cara Therapeutics reports second quarter 2017 financial results

BRIEF-Cara Therapeutics appoints Mani Mohindru CFO

* Cara Therapeutics appoints Mani Mohindru, Ph.D., chief financial officer

BRIEF-Cara Therapeutics says ‍phase 1 results showed all four tablet strengths of oral CR845 were generally well-tolerated​

* Cara Therapeutics announces summary data from phase 1 trial of oral cr845 in hemodialysis patients with chronic kidney disease

Cara's chronic pain drug data disappoints, shares plunge

Cara Therapeutics Inc reported disappointing data from a key study testing its chronic pain treatment in patients with osteoarthritis, sending the drug developer's shares down about 32 percent after the bell on Thursday.

Cara reports mixed results from pain drug trial, shares plunge

Cara Therapeutics Inc on Thursday reported mixed results from a pivotal trial testing the drug developer's chronic pain treatment in patients with osteoarthritis of the knee or hip.

BRIEF-Cara Therapeutics announces top-line results from phase 2B trial

* Cara Therapeutics announces top-line results from phase 2B trial of oral CR845 in chronic pain patients with osteoarthritis of the hip or knee

BRIEF-Cara receives breakthrough therapy designation from FDA for I.V. CR845

* Cara receives breakthrough therapy designation from FDA for I.V. CR845 for the treatment of chronic kidney disease-associated pruritus in hemodialysis patients Source text for Eikon: Further company coverage:

BRIEF-Cara Therapeutics reports continuation of phase 3 trial of I.V. CR845 in postoperative pain

* Cara Therapeutics reports continuation of phase 3 trial of i.v. Cr845 in postoperative pain following interim assessment

BRIEF-Cara Therapeutics Q1 loss per share $0.81

* Cara Therapeutics reports first quarter 2017 financial results

BRIEF-Cara Therapeutics announces positive data

* Cara Therapeutics announces positive data from quantitative phase 1 trial measuring respiratory safety of I.V. CR845

BRIEF-Cara Therapeutics announces proposed offering of common stock

* Cara Therapeutics announces proposed offering of common stock

BRIEF-Cara Therapeutics announces positive top-line data from Part A of Phase 2/3 Trial of I.V. CR845 in chronic kidney disease-associated pruritus

* Cara Therapeutics announces positive top-line data from part A of phase 2/3 trial of I.V. CR845 in chronic kidney disease-associated pruritus

BRIEF-Cara files for mixed shelf of up to $250.0 mln

* Files for mixed shelf of up to $250.0 million - sec filing Source text for Eikon: Further company coverage:

BRIEF-Cara Therapeutics Q4 loss per share $0.81

* Cara Therapeutics reports fourth quarter and full year 2016 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up